Pune-based Serum Institute of India (SII), the world's largest vaccine maker in terms of doses, has stockpiled around 40-50 million doses of its Covid-19 vaccine candidate, Covishield, reports Economic Times.
According to the report, India will initially get most of the vaccine shots stockpiled by the company as the exports of the Covishield would require the World Health Organisation's (WHO) pre-qualification, which is likely to take around a month after regulatory approval.
SII's CEO Adar Poonawalla has said that the company expects to receive the emergency use approval from the Drug Controller General of India (DCGI) for the vaccine in the next few days. He said that the stockpiled doses of 'Covishield' are being augmented every week.
Poonawalla further said that the roll-out of the vaccine can be expected in January.
“We will get some good news this new year...All the data has been submitted and we must respect the process as regulators are evaluating data,” Poonawalla was quoted as saying.
“Once we get regulatory approvals in a few days, it will depend upon the government to decide how much they can take and how fast,” he added.
SII reportedly plans to manufacture 100 million doses by March 2021. After its third facility becomes operational in March, the company aims to increase the production to 300 million doses by July.
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 999/year is the best way you can support our efforts.